JP2021518162A5 - - Google Patents

Info

Publication number
JP2021518162A5
JP2021518162A5 JP2020573082A JP2020573082A JP2021518162A5 JP 2021518162 A5 JP2021518162 A5 JP 2021518162A5 JP 2020573082 A JP2020573082 A JP 2020573082A JP 2020573082 A JP2020573082 A JP 2020573082A JP 2021518162 A5 JP2021518162 A5 JP 2021518162A5
Authority
JP
Japan
Prior art keywords
item
modified
immunoeffector
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022366 external-priority patent/WO2019178422A1/en
Publication of JP2021518162A publication Critical patent/JP2021518162A/ja
Publication of JP2021518162A5 publication Critical patent/JP2021518162A5/ja
Priority to JP2024070727A priority Critical patent/JP2024091902A/ja
Pending legal-status Critical Current

Links

JP2020573082A 2018-03-15 2019-03-14 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 Pending JP2021518162A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024070727A JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201862643578P 2018-03-15 2018-03-15
US201862643582P 2018-03-15 2018-03-15
US62/643,578 2018-03-15
US62/643,582 2018-03-15
US201862692014P 2018-06-29 2018-06-29
US201862692010P 2018-06-29 2018-06-29
US62/692,010 2018-06-29
US62/692,014 2018-06-29
US201862714333P 2018-08-03 2018-08-03
US201862714337P 2018-08-03 2018-08-03
US62/714,337 2018-08-03
US62/714,333 2018-08-03
US201862768462P 2018-11-16 2018-11-16
US201862768459P 2018-11-16 2018-11-16
US201862768430P 2018-11-16 2018-11-16
US201862768428P 2018-11-16 2018-11-16
US62/768,462 2018-11-16
US62/768,428 2018-11-16
US62/768,459 2018-11-16
US62/768,430 2018-11-16
US201962804259P 2019-02-12 2019-02-12
US62/804,259 2019-02-12
PCT/US2019/022366 WO2019178422A1 (en) 2018-03-15 2019-03-14 Gene-regulating compositions and methods for improved immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024070727A Division JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Publications (2)

Publication Number Publication Date
JP2021518162A JP2021518162A (ja) 2021-08-02
JP2021518162A5 true JP2021518162A5 (https=) 2022-03-18

Family

ID=67903888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573082A Pending JP2021518162A (ja) 2018-03-15 2019-03-14 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2024070727A Pending JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024070727A Pending JP2024091902A (ja) 2018-03-15 2024-04-24 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法

Country Status (9)

Country Link
US (2) US20190284529A1 (https=)
EP (1) EP3765608A4 (https=)
JP (2) JP2021518162A (https=)
KR (2) KR20200133218A (https=)
CN (1) CN112041433A (https=)
AU (2) AU2019236205A1 (https=)
BR (1) BR112020018573A2 (https=)
CA (1) CA3093968A1 (https=)
WO (1) WO2019178422A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20220081691A1 (en) * 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
WO2020081764A1 (en) * 2018-10-18 2020-04-23 Synerk Inc. Compositions and methods for inhibiting tigit gene expression
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
US20220096551A1 (en) * 2019-01-28 2022-03-31 Bar Ilan University Combinations, nanoparticles and methods for controlling natural killer cell activation and function
CN113396216A (zh) * 2019-02-04 2021-09-14 Ksq治疗公司 用于改进的免疫疗法的组合基因靶标
WO2020174472A1 (en) * 2019-02-26 2020-09-03 Rambam Med-Tech Ltd. Cells and methods for improved immunotherapy
US12188045B2 (en) 2019-06-07 2025-01-07 KSQ Therapeutics, Inc. Guide RNA combinations and methods of use
KR20220121814A (ko) * 2019-11-27 2022-09-01 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 종양 미세 환경에서 면역 억제를 극복하기 위한 조작된 t 세포 및 종양 침윤성 림프구
JP2023504081A (ja) * 2019-11-27 2023-02-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽細胞腫及び他の癌を処置するためのナチュラルキラー細胞免疫療法
CN115003315A (zh) * 2019-12-04 2022-09-02 莫纳什大学 使用ptp1b和ptpn2抑制剂激活细胞毒性白细胞的方法
EP4073242A4 (en) * 2019-12-12 2024-01-03 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
WO2021119555A2 (en) * 2019-12-12 2021-06-17 Kumquat Biosciences Inc. Compositions and methods for potentiating immune response
EP3845646A1 (en) * 2019-12-30 2021-07-07 Secarna Pharmaceuticals GmbH & Co. KG Modified antisense oligonucleotide for inhibition of foxp3 expression
CN113151178B (zh) * 2020-01-07 2022-09-09 清华大学 敲除Rc3h1基因和/或Zc3h12a基因的重组T细胞及其应用
EP4239059A4 (en) 2020-11-19 2024-05-15 Suzhou Grit Biotechnology Co., Ltd. METHOD FOR CULTIVATION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
WO2022109498A1 (en) * 2020-11-23 2022-05-27 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
EP4255453A4 (en) * 2020-12-03 2025-03-26 Nkarta, Inc. Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
JP7847451B2 (ja) * 2021-03-02 2026-04-17 花王株式会社 アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法
EP4333860A4 (en) * 2021-05-07 2025-06-04 Board of Regents, The University of Texas System SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
CN113234834A (zh) * 2021-07-09 2021-08-10 北京泱深生物信息技术有限公司 一组用于胰腺癌预后的基因及其应用
WO2023015213A1 (en) * 2021-08-03 2023-02-09 Spotlight Therapeutics Ptpn2 specific guide rnas and uses thereof
CN117616115A (zh) * 2021-08-03 2024-02-27 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
CN113430202A (zh) * 2021-08-26 2021-09-24 山东兴瑞生物科技有限公司 一种具有高敲除率的人PD1基因sgRNA及含有该sgRNA的质粒、T细胞
US20240390493A1 (en) * 2021-09-29 2024-11-28 The Johns Hopkins University Methods and compositions to augment efficacy and reduce toxicity of non-engrafting, cd8-depleted allogenic donor lymphocyte infusions
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
GB202114871D0 (en) * 2021-10-18 2021-12-01 Ucl Business Ltd Guide RNA and uses thereof
CN114134177B (zh) * 2021-11-19 2022-11-08 中国医学科学院血液病医院(中国医学科学院血液学研究所) 敲除Setd5的小鼠模型和抵御急性T淋巴细胞白血病小鼠模型的构建方法和应用
WO2023143515A1 (zh) * 2022-01-29 2023-08-03 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
WO2023184107A1 (en) * 2022-03-28 2023-10-05 Huigene Therapeutics Co., Ltd. Crispr-cas13 system for treating mecp2-associated diseases
EP4260932A1 (en) 2022-04-13 2023-10-18 GEA Process Engineering A/S Method and system for reducing water consumption in a membrane dealcoholization process
EP4276174A1 (en) * 2022-05-09 2023-11-15 Cellectis S.A. Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)
WO2024044672A2 (en) * 2022-08-24 2024-02-29 The Board Of Trustees Of The Leland Stanford Junior University A multiplexed rna regulation platform for primary immune cell engineering
PE20251319A1 (es) * 2022-09-13 2025-05-16 Arsenal Biosciences Inc Celulas inmunitarias que coexpresan arnhc de tgfbr
EP4382118B1 (en) * 2022-12-07 2025-08-20 Eberhard Karls Universität Tübingen, Medizinische Fakultät Modified immune cell
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
KR102637929B1 (ko) * 2023-08-07 2024-02-20 충남대학교 산학협력단 면역관문 억제제의 효능 예측용 pbrm1 유전자 마커및 이의 용도
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015578A4 (en) * 1997-09-17 2004-12-01 Walker And Eliza Hall Inst Of THERAPEUTIC MOLECULES
US20160017286A1 (en) * 2013-03-06 2016-01-21 The Trustees Of The University Of Pennsylvania Ikaros inhibition to augment adoptive t cell transfer
AU2014266833B2 (en) * 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
EP3154555A4 (en) * 2014-06-10 2018-02-28 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
RU2018105118A (ru) * 2015-08-21 2019-09-23 Пфайзер Инк. Терапевтические наночастицы, содержащие терапевтический агент, и способы их получения и применения

Similar Documents

Publication Publication Date Title
JP2021518162A5 (https=)
JP2021518161A5 (https=)
JP2021518160A5 (https=)
JP7551815B2 (ja) Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製
JP2022519595A5 (https=)
CN110168078B (zh) 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
KR102495308B1 (ko) 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
CN116322716A (zh) Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
KR20210008502A (ko) 암을 치료하기 위한 방법 및 조성물
US20200017881A1 (en) Programmable Oncolytic Virus Vaccine System and Method
AU2020214807A1 (en) Microenvironment sensors to regulate engineered gene expression
JP2025156332A (ja) エクスビボ細胞療法用途のための免疫細胞の操作
WO2023123195A1 (zh) 一种目的基因可调控的工程化免疫细胞及其制备方法和应用
US20260108604A1 (en) Car t cell compositions for treatment of cancer
US20240150711A1 (en) Personalized redirection and reprogramming of t cells for precise targeting of tumors
Chen et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy
CA3256913A1 (en) NUCLEIC ACID MODIFIED BIOLOGICAL CELL WITH EXPANSION-DEPENDENT GENE EXPRESSION
JP2010521460A (ja) 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
Navarre et al. Dendritic cells accelerate CAR T cells in irradiated tumors through chimeric synapses
WO2020190936A1 (en) Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor
Kong et al. Enhancement of NK cell activity via DNA-sensing inhibition by Poxin transgene
Babu et al. Cancer gene therapies progress in pre and postgenomics era
WO2025146440A1 (en) Use of lmo4 to bolster stemness and antitumor efficacy of t-cells
Hagner et al. 646. Covalently-Closed, Dumbbell-Shaped Double-Stem-Loop DNA Constructs (dSLIM) with Specific Immunomodulatory Function
Yoon et al. 116. Overcoming CAR-Dependency of Oncolytic Adenovirus via Adenoviral Fiber Modification with Vesicular Stomatitis Virus Glycoprotein Epitope for Enhanced Antitumor Efficacy